NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

NCT06405490 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Nanoliposomal Irinotecan
Cadonilimab
Oxaliplatin
Capecitabine
First-Line
Advanced Cancer
Pancreatic Adenocarcinoma
Drug Use

Interventions

DRUG: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences